-
Company Insights
New![]()
Innovation and Patenting activity of Nien Made Enterprise Co Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Nien Made Enterprise Co Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report...
-
Thematic Analysis
New![]()
Cybersecurity in Medical Devices – Thematic Intelligence
Cybersecurity remains a priority for enterprises The tech industry is experiencing significant upheaval. Big Tech has made mass layoffs to cut costs, and cybersecurity companies are not immune. However, while information technology (IT) budgets face scrutiny as companies cut discretionary spending, cybersecurity will remain a priority. Cyber risk is higher than ever, and the consequences of attacks are significant. According to Cybersecurity Ventures, global cybercrime will reach $10.5 trillion annually by 2025. Tackling this issue requires investment, and GlobalData forecasts...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Mitapivat Sulfate in Acquired (Autoimmune) Hemolytic Anemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Mitapivat Sulfate in Acquired (Autoimmune) Hemolytic Anemia Drug Details: Mitapivat sulfate (Pyrukynd) act as anti...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Mitapivat Sulfate in Beta Thalassaemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Mitapivat Sulfate in Beta Thalassaemia Drug Details: Mitapivat sulfate (Pyrukynd) act as anti anemic agent....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Fidanacogene Elaparvovec in Hemophilia B (Factor IX Deficiency)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Fidanacogene Elaparvovec in Hemophilia B (Factor IX Deficiency) Drug Details: Fidanacogene elaparvovec (SPK-9001, PF-06838435)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vutrisiran in Familial Amyloid Cardiomyopathy
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDataÂ’s proprietary machine learning algorithms developed using over 10 years of historical data. Vutrisiran in Familial Amyloid Cardiomyopathy Drug Details: Vutrisiran (Amvuttra) is designed to target and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CRX-100 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDataÂ’s proprietary machine learning algorithms developed using over 10 years of historical data. CRX-100 in Solid Tumor Drug Details: CRX-100 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Astrorx in Amyotrophic Lateral Sclerosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Astrorx in Amyotrophic Lateral Sclerosis Drug Details: Stem cell therapy (AstroRx) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Mitapivat Sulfate in Alpha Thalassaemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Mitapivat Sulfate in Alpha ThalassaemiaDrug Details:Mitapivat sulfate (Pyrukynd) act as anti anemic agent. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMU-131 in Gastric Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IMU-131 in Gastric Cancer Drug Details: IMU-131 (Her-Vaxx) is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.